Eplerenone [Usan] en es it fr

Eplerenone [Usan] Brand names, Eplerenone [Usan] Analogs

Eplerenone [Usan] Brand Names Mixture

  • No information avaliable

Eplerenone [Usan] Chemical_Formula


Eplerenone [Usan] RX_link


Eplerenone [Usan] fda sheet

Eplerenone_[Usan] FDA

Eplerenone [Usan] msds (material safety sheet)

Eplerenone [Usan] Synthesis Reference

No information avaliable

Eplerenone [Usan] Molecular Weight

414.491 g/mol

Eplerenone [Usan] Melting Point

No information avaliable

Eplerenone [Usan] H2O Solubility

Slightly soluble

Eplerenone [Usan] State


Eplerenone [Usan] LogP


Eplerenone [Usan] Dosage Forms

Tablet (film-coated - 25, 50 mg)

Eplerenone [Usan] Indication

For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.

Eplerenone [Usan] Pharmacology

Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

Eplerenone [Usan] Absorption

The absolute bioavailability of eplerenone is unknown.

Eplerenone [Usan] side effects and Toxicity

The most likely symptoms of human overdosage would be anticipated to be hypotension or hyperkalemia. However, no cases of human overdosage with eplerenone have been reported.

Eplerenone [Usan] Patient Information

Eplerenone [Usan] Organisms Affected

Humans and other mammals